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The effectiveness of IL-2 in the enhancement of immune 
responses in B6-AKR and normal B6 mice was investigated. In 
vivo treatment of chimeras with murine IL-2 partially 
restored PFC response s of their splenocytes to SRBC. This 
treatment suppressed splenocyte IL-2 production in chimeras. 
In vivo treatment of chimeras with rhIL-2 resul ted in a 
slight enhancement of mitogenic responses to Con-A. This 
treatment had no significant effect on mitogenic responses 
to PHA. The rhIL-2 treatment did not result in suppression 
of IL-2 production by chimeric ~plenocytes. 
Recombinant human IL-2 enhanced mitogenic responses of 
normal B6 and chimeric mice to PHA in all age groups tested. 
However, the mitogenic response to Con-A was enhanced only 
in older mice (130 days post-transplant). 
The duration of rhIL-2 exposure time was critical for 
the enhancement of mitogenic responses of B6 splenocytes to 
PHA. The enhancement of thymocyte mitogeneic responses to 
Con-A or PHA was also dependent on the length of incubation 
time with rhIL-2. However, the enhancement of Con-A 
mitogenesis was independent _of the duration of exposure time 
to rhIL-2. 
Treatment of mitogen-stimulated splenocytes with 7D4 
antibody greatly inhibited cell proliferation of several 
concentrations of mitogen tested. The 7D4 antibody 
significantly inhibited the response of thymocytes cultured 
with rhIL-2 to PHA or Con-A. Studies with 7D4 antibody 
provided direct evidence for the involvement of IL-2 in the 
proliferation of splenocytes to T-cell mitogens and the 
proliferation of thymocytes in co-stimulatory assays. 
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Bone Marrow Transplantation 
There has been an increasing growth in the use of bone 
marrow transplantation (BMT) for the treatment of immuno-
deficiency, severe aplastic anemia and leukemia (1). This 
has been the result of technological advancements in marrow 
preparation leading to successful BMT in humans (1), and 
experimental animals (2-7). Allogeneic BMT in humans has 
been limited to major histocompatibility complex (MHC) -
matched (HLA), and non-mixed lymphocyte culture (MLC)-
reactive donor-recipient combinations. This limitation is 
due to the high risk of severe graft-versus-host disease 
(GVHD) when histoincompatible combinations are used. 
Approximately 35 to 40% of prospective marrow transplanted 
patients have an HLA-identical sibling who can serve as a 
marrow donor (1). An important objective in BMT research is 
to make this form of treatment available to patients who 
lack HLA-matched donors. 
There are two major problems associated with transplan-
tation of allogeneic bone marrow. These problems are 
directly related to the presence of two sets of immune 
cells. The first consisting of the recipient's immune 
system ( fu_nctional T-cells), .attempts to reject the 
transplanted bone marrow. This results in a 
host-versus-graft response (HVGR). The second problem 
occurs with immunocompetent cells present in the marrow 
graft (mature T-cells) which react against the recipient, 
resulting in GVHD (8). 
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Studies of allogeneic BMT have shown that T-cells which 
contaminate bone marrow grafts play a major role in the 
induction of GVHD (2-5). The depletion of T-cells from such 
grafts in vitro with monoclonal anti-T-cell antibody and 
complement completely protected animals from lethal GVHD (4, 
5, 8, 9). Lethally irradiated mice which were infused with 
allogeneic bone marrow treated with anti-Thy 1 with or 
without complement, survived for 100 to 170 days post-
transplant • . This treatment also resulted in complete 
chimerism and immunocompetence of these chimeras (2, 3, 4). 
Krown et al. (9) reported the construction of H-2 
al!ogeneic chimeras using C57BL/6J (B6) 
b (H-2 ) donors and 
irradiated CBA/J (H-2k) mice as recipients. No evidence of 
GVHD was apparent in these chimeras when marrow was treated 
with anti-Thy 1.2 and complement prior to infusion. 
Experimental models using AKR mice (H-2k) have also 
been developed for evaluating allogeneic BMT procedures 
(2,3,7,10). The AKR strain of mice develop spontaneous 
leukemia between 6 to 12 months of age (2,3,7). Tanaka et 
al. (7) reported that AKR mice could be protected from the 
development of spontaneous leuk~mia by infusion of 
allogeneic marrow which was matched at the H-2 locus of the 
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recipient. The infusion of CBA/H ( H-2k·) marrow rendered AKR 
mice leukemia resistant. These stable CBA/H-AKR chimeras 
continued to live for 14 to 18 months without evidence of 
leukemia. "-
The development of spontaneous leukemia in AKR mice has 
also been prevented by infusion of allogeneic marrow from 
donors not matched at the H-2 locus. Onoe et al. ( 2 ) 
r~ported the preparation of long-lived allogeneic chimeras 
in which donors and recipients differed at the MHC barrier. 
Allogeneic chimeras [B6-AKR] showed no evidence of GVHD when 
anti-Thy 1.2 antise~um-treated_marrow cells were infused 
into lethally irradiated AKR recipients. Thymus and spleen 
cells of these chimeras were shown to be predominantly of 
donor type. Immune functions in these chimeras were 
analyzed approximately 100 days post-
transplant (2). These studies reported normal proliferative 
responses of chimeric splenocytes to concanavalin A (Con-A), 
phytohemagglutinin (PHA) and lipopolysaccharide (LPS). 
Natural killer (NK) cell and antibody-dependent cell 
.. 
mediated cytotoxic activity were also within a normal range. 
However, primary antibody responsiveness to sheep red blood 
cells (SRBC) failed to develop in these chimeras. Longley 
and Good (3) performea further analysis of long-term 
survival and immune functions of fully allogeneic B6-AKR and 
allogeneic CBA-AKR chimeras. The infusion of lethally · 
irradiated AKR (H-2k) recipients with MHC-matched marrow 
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from CBA/J (H-2k) mice or MHC-mismatched marrow from B6 
(H-2b) mice, protected AKR mice from the development of 
spontaneous leukemia. Ninety-eight percent of H-2 
compatible allogeneic chimeras [CBA-AKR] were still alive 
280 days post-transplant. However, B6-AKR chimeras began 
dying 170 days post-transplant due to a wasting syndrome of 
undetermined etiology (3). In contrast to normal responses 
observed in CBA-AKR chimeras, B6-AKR chimeras (170 to 280 
days post-transplant) showed suppressed Con-A mitogenesis 
and deficient interleukin-2 (IL-2) production. Primary 
antibody responses to both in vitro and in vivo stimulation 
with SRBC were also deficient in these chimeras. The 
addition of purifi~d rat IL-2 to splenocyte cultures of 
long-lived (170 to 280 days post-transplant) chimeras 
restored the deficient in vitro antibody responses to SRBC. 
It was further demonstrated that in vivo administration of 
murine IL-2, 48 hr prior to analysis, restored in vitro 
antibody responses. Normal antibody response to a secondary 
challenge with SRBC in vivo has been previously reported 
(2,3), in similar chimeric combinations. These findings 
suggest the presence of necessary cellular elements required 
for T-dependent antibody responses of chimeric splenocytes. 
Onoe et al. (11) reported the existence of a minor 
subpopulation of helper T-cells in similar chimeras. This 
subpopulation could expand and interact with antigen 
presenting cells of donor type (H-2I incompatible) upon 
repeated or continued stimulation with SRBC. Matching of 
T-cells and antigen presenting cells was required for the 
primary antibody response to SRBC. Onoe et al. (12) 
reported that T-cells from chimeras cooperated with 
non-T-cells bearing recipient type MHC antigens. The 
addition of adherent cells of recipient MHC type in which 
matches involved IE and IA compatibility corrected the 
deficient primary antibody response to SRBC (11,12). 
Activation of T-cells by Mitogens 
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A number of substances, primarily plant lectins, have 
been shown to activate T-cells _ ( 13-17) • The term "lectin 11 
refers to a large group of multimeric glycoproteins. These 
glycoproteins bind and cross-link specific carbohydrate 
determinants displayed on the surface of lymphocytes (17). 
Some lectins trigger a large proportion of lymphocytes to 
divide and synthesize DNA (13-17). These type of lectins 
are referred to as mitogens. Mitogenic lectins are 
routinely used to study early biochemical events involving 
lymphocyte activation. Mitogen stimulation of lymphocytes 
in vitro is believed to mimic a series of events which 
occurs in vitro following the stimulation with specific 
antigens (13-19). Mitogens are selective in their 
stimulatory effects on Band T lymphocytes (15-19). Two of 
the most commonly used mitogens, PHA and Con-A, specifically 
activate T-cells in both human (_18), and mouse lymphoid ·cell 
populations (15-19). Other mitogens, such as LPS and 
pokeweed mitogen (PWM) specifically activate B-cells (14, 
15). 
Both Con-A and PHA stimulate DNA synthesis and blast 
6 
transformation of splenic lymphocytes (13-17). In general, 
Con-A stimulation results in greater proliferative responses 
of T-cells at various cell densities, mitogen concentrations 
and culture durations compared to PHA (17). The stimulation 
of T-cells occurs at a certain concentration range of these 
mitogens (15-17). Differential capacities of various 
lymphoid populations in response to PHA and Con-A were 
described by Stobo et al. (17). They demonstrated that 
Con-A activates DNA synthesis in thymocytes, cortisone-
treated thymocytes and spleen cells. In contrast, PHA 
stimulation results in minimal proliferation of thymocytes. 
Despite the heterogeneity of mouse lymphoid cell populations 
in their responses to mitogens, similar amounts of 
radiolabeled mitogen ([ 125 I] PHA, [ 125 I] Con-A) binds to the 
surface of all lymphoid cells (17). The quantity of mitogen 
bound is dependent on the temperature, concentration and 
duration of the mitogen pulse. The binding of mitogen to 
its cell surface receptor is rapid, being complete in 
· 1 30 mi·nutes at 37°C. approximate y However, a prolonged 
contact between mitogen and T-cells is required for optimal 
stimulation (16-17). The induction of DNA synthesis in 
lymphocytes requires at least a 20 hr exposure to the 
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mitogen. More than 48 hr contact with the mitogen is 
required for optimal thymidine incorporation on day 3 and 4 
(16). These observations suggest that binding is necessary 
but not a sufficient cause for activation. Since thymus 
cells bind to both PHA and Con-A, but only Con-A results in 
thymocyte stimulation, it has been suggested that binding of 
the mitogen to the cell surface is not the only requirement 
for cell activation (17). Cell activation events lead to 
cellular proliferation which is dependent on the continued 
presence of other factors liberated by the cells themselves. 
These factors, known collectively as "lymphokines", regulate 
cell proliferation and subsequent growth of a number of cell 
types (20-23). 
IL-2 
Since it was discovered that IL-2 regulates T-cell 
growth, it has been a focus of scientific research (20-27). 
Interleukin-2, formerly known as T-cell growth factor 
(TCGF), is a glycoprotein synthesized and secreted by 
activated T-cells. Interleukin-2 functions as a 
hormone-like growth factor for many subsets of T-cells (20). 
Interleukin-2 dependent murine cell lines such as, HT-2 (21) 
and CTLL-2 (22), have been established. These cell lines 
have made possible the development of a standard quantita-
tive microassay for the detection of IL-2 in cell culture 
supernatants (26). This development,in turn, has aided the 
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study of biochemical and functional characteristics of this 
lymphokine. 
In the murine system, IL-2 (TCGF} was originally 
described as an activity which was present in the 
supernatants of Con-A stimulated spleen cells. These 
supernatants supported the proliferation of both cytotoxic 
and helper T-cells in culture (23,26}. Maximum IL-2 
activity was detected 12 to 48 hr after Con-A stimulation 
(23,27}. 
The production of IL-2 is T-cell specific. Mature Thy 
l+ cells are required for this _production and only T-Fell 
lectins can elicit IL-2 release (20,23,27}. However, both 
T-cells and adherent cells (macrophages} participate in the 
production of IL-2. Activated macrophages produce 
interleukin-I (IL-1) which in turn stimulates T-cells to 
release IL-2 (20,27,28). 
Interleukin-2 induces the clonal expansion of T-cells 
for the generation of T-cell immune responses (20-27}. 
Smith et al. (29} reported that T-cells activated by lectin 
or antigen could absorb IL-2 activity in a time and cell 
concentration dependent manner. These cells continued to 
proliferate following this absorption process. Gillis et 
al. (26} observed that T-cell lectins, alone, could not 
support the continuous proliferation of T-cells. However, 
,I 
conditioned medium containing both lectin and IL-2, 
initiated and sustained T-cell growth. These observations 
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have suggested that IL-2 itself functions as a T-cell 
mitogenic signal rather than lectin or antigen (26,30,31). 
Experiments utilizing monoclonal antibody directed against 
the IL-2 molecule have provided further evidence that IL-2 
production is obligatory for T-cell mitogenesis. Gillis et 
al. (32) reported that the addition of monoclonal anti-IL-2 
IgG to cultures of Con-A stimulated murine splenocytes 
inhibited mitogen-induced proliferation. However, an 
initial signal supplied by the binding of mitogen to the 
cell membrane has been shown to be a requirement for the 
activation of T-cells. This activation leads to an IL-2 
responsive state (20,23,27). Although, mature T-cells 
produce IL-2 (20,23), both mature and immature T-cells 
respond to IL-2. Smith et al. (27) reported that thymocytes 
(immature T-cells), and mature splenocytes responded to the 
proliferative stimulus of IL-2. These findings suggested 
that IL-2 responsive and IL-2 producing cells might belong 
to distinct subsets. Wagner and Rollinghoff (33) reported 
- + + . that cytotoxic T-cells (Lyl 2 3 ) proliferated in response 
+ - -to IL-2, while helper T-cells (Lyl 2 3 )were involved in 
IL-2 production. 
Murine and human IL-2 have been purified by gel 
filtration, ion exchange chromatography, and isoelectric 
focusing (24,23). Analysis of the biochemical and 
biological properties of IL-2 has revealed species 
differences in ·its function and molecular weight (MW) 
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(20,24). Murine IL-2 has a MW of 30,000 while human IL-2 
has a MW of 15,000 (24). Species differences in biological 
activity of IL-2 were first reported when the mitogenic 
effects of IL-2 from humans, rats, and mice were compared 
(20,24). Human and rat IL-2 promoted the proliferation of 
murine T-cells, while murine and rat IL-2 had no detectable 
activity on human T-cells. 
Human IL-2 supports the growth of T-cell populations 
activated in vitro (34). Human IL-2 enhances thymocyte 
mitogenesis (35), and induces T-helper cells for antibody 
forming responses (36). It also regulates the activity of 
cytotoxic T-cells (37) NK cells (38), and lymphokine 
activated killer (LAK) cells (39). 
Human IL-2 is produced in minute quantities by 
peripheral blood lymphocytes upon stimulation with T-cell 
lectins (40). The need for large amounts of purified IL-2 
prompted the isolation and cloning of the human IL-2 gene. 
The availability of recombinant human IL-2 (rhIL-2) has 
greatly facilitated its biological and clinical study 
(40-42). The imrnunomodulatory properties of rhIL-2 have 
been tested in a variety of in vitro and in vivo murine 
immunological assays (40-42). These studies have revealed 
that native IL-2 and rhIL-2 function equivalently. 
Recombinant human IL-2 provides significant helper activity 
for the stimulation of both human and mouse lymphocyte 
proliferation (40-42). 
IL-2 Receptor 
The current model of lectin-stimulated T-cell 
activation proposes that interaction of the lectin with 
T-cells induces expression of IL-2 specific receptors 
(30,31,43,44). Concanavalin A stimulates polyclonal 
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proliferation of T-cells by inducing the production of IL-2, 
and its membrane receptors (43,45,46). A model of 
ligand-activated IL-2-induced proliferation of T-ce l ls has 
been developed (43). According to this model, ligand 
(antigen or mitogen) induces the production of IL-2 by 
helper T-cells, and the expres~ion of the IL-2 receptor on 
responder T-cells. The responder cells, in turn, 
proliferate upon the binding of IL-2 to its receptor. 
Interleukin-2 receptor expression on responder cells 
requires a specific interaction of ligand with selective 
sites on the cell membrane. 
The demonstration of an IL-2 specific binding site has 
been made possible with the development of a radiolabeled 
IL-2 binding assay (45). The binding of [ 35s] methionine-
IL-2 to CTLL-2 cells proceeds rapidly at 37°c and reaches a 
maxium level within 15 minutes. The binding is specific, 
saturable, and occurs with high affinity. There is a close 
correlation between the concentration of IL-2, the 
proliferative response, and the occupation of the IL-2 
receptor site (45). Interleukin-2 receptors are detectable 
4 hr after mitogen stimulation. Maximum levels of IL-2 
12 
receptors occur between 24 to 48 hr after culture initiation 
(46). Two classes of IL-2 receptor binding sites have been 
identified according to their affinity for IL-2 (47). The 
lower affinity site accounts for 85 to 95% of IL-2 receptors 
expressed on the surface of activated T-cells. The 
remaining receptors (10%) exhibit a higher affinity binding 
site. The proliferative response of T-cells to mitogenic 
stimuli is believed to be the result of the interaction of 
IL-2 with the high affinity form of its receptor (47,48). 
Monoclonal antibodies that detect IL-2 receptors have 
been recently reported by seve~al laboratories (49-51). The 
7D4 rat IgM monoclonal antibody described by Malek et al. 
(49) recognizes epitopes distinct from the IL-2 binding site 
on murine T-cells. This antibody has been shown to inhibit 
IL-2 dependent cell proliferation of HT-2 and CTLL-2 cells, 
without inhibiting IL-2 binding (49). The level of 
inhibition of proliferation is dependent on both antibody 
and IL-2 concentration. Maximal inhibition occurs at low 
IL-2 and high antibody concentrations (49). It has been 
suggested that 7D4 may selectively reduce the affinity of 
high affinity IL-2 receptors. This reduction of receptor 
affinity could result in suppression of IL-2 dependent cell 
proliferation without inhibition of IL-2 binding (49). 
It is difficult to detect a significant IL-2 receptor 
bearing T-cell population in ~nstimulated spleen cell 
cultures (45,49). However, non-specific stimulation with 
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mitogen in vitro results in a significant increase in the 
expression of high affinity IL-2 receptors. Concanavalin A 
stimulated cells bear significantly higher numbers of IL-2 
receptors than PHA stimulated cells (46). The level of IL-2 
receptor expression is dependent on the mitogen 
concentration (46). 
The physiologically limiting variables which determine 
the magnitude of T-cell proliferative responses are IL-2 
concentration, receptor expression and receptor affinity 
(20,30,45,49). 
The objective of the present study was to analyze the 
effectiveness of IL-2 in the eQhancement of immune responses 
in AKR mice made leukemia resistant by infusion with 
allogeneic bone marrow. The effect of in vivo treatment of 
B6-AKR chimeras with crude preparations of murine IL-2 on 
primary antibody response to in vivo sensitization with SRBC 
was measured. The in vivo effect of rhIL-2 on mitogenic 
responses of chimeric splenocytes to PHA and Con-A was also 
analyzed. The immunological state of B6-AKR chimeras at 
various days following transplant was compared to 
age-matched normal B6 controls. The proliferative responses 
of their splenocytes to Con-A, PHA and rhIL-2 were compared. 
Kinetic studies were performed on the enhancing effect of 
rhIL-2 on proliferative responses of B6 splenocytes and 
thymocytes to PHA and Con-A. The contribution of IL-2 in 
the proliferative response of splenocytes and thymocytes to 
PHA or Con-A was tested by using anti-IL-2 receptor 
monoclonal antibody 7D4. 
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MATERIALS AND METHODS 
Animals 
AKR/J and B6 male and female mice were used in this 
study (Jackson Laboratory, Bar Harbor, ME). 
Culture Medium 
All assays were performed in complete medium consisting 
of RPMI 1640 (KC Biological, Lenexa, KS) supplemented with 
10% heat inactivated fetal bovine serum (Sigma Biological 
Co., St. Louis, MO), 100 units (U) per ml penicillin, 100 
ug/ml streptomycin, -5 5.0 x 10 M mercaptoethanol, and 2 mM 
1-glutamine (KC Biological). 
Preparation of Bone Marrow Cells 
Marrow cells were prepared under sterile conditions in 
a manner similar to that described by Once et al. (2). 
Donor marrow was obtained from B6 mice. Donors were 
sacrificed by cervical dislocation. Bone marrow cells were 
obtained from tibia and femur by gentle aspiration with 
complete medium using a 25 gauge needle and syringe. The 
resulting cell suspension was placed on ice for 5 minutes to 
allow the cellular debris to settle to the bottom of the 
tube. The supernatant was removed, and centrifuged at 
400 X g. The cell pellet was gently resuspended in complete 
medium and viable (trypan blue exclusion) cell counts were 
determined. 
. 8 
Marrow suspensions were adjusted to 1.0 x 10 
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cells/ml and were mixed with an equal volume of a 1:10 
dilution of anti-Thy 1.2 alloantiserum (Accurate Chemical 
and Scientific Corp. Westbury, NY). Cells were incubated on 
ice for 30 minutes with occasional mixing. The cell 
suspension was washed 3 times with complete medium, and the 
concentration adjusted to 5.0 x 107 cells/ml. 
Preparation of Bone Marrow Chimeras 
Chimeras were prepared as described (2). Female AKR/J 
mice, 10 to 12 weeks old, were used as irradiated recipients 
of marrow cells. Mice were placed in a plastic chamber and 
received a whole body dose of 10 Gy (dose rate= 2.0 
Gy/minute) from a linear accelerator at Florida Hospital, 
Orlando FL. Approximately 2 to 4 hr following irradiation, 
mice were infused via tail vein with 0.5 ml (2.5 x 10 7 
cells) of the donor marrow suspension. Chimeras were placed 
in sterile micro-isolator cages and provided with sterile 
food and water ad libitum. 
Production of Murine IL-2 
EL-4.IL-2 thymoma cells (American Type Culture 
Collection, Rockville, MD) were cultured in complete medium. 
EL-4.IL-2 cells were harvested from cultures and washed once 
with complete medium. Cells were resuspended to a 
concentration of 2.0 x 106 cells/ml in RPMI 1640 medium with 
5% serum. Cells were cultured in Corning tissue culture 
flasks (Corning Glass Works, Corning, NY) for 48 hr in the 
presence of an equal volume (40 ng/ml) of phorbol 
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12-myristate 13-acetate (Sigma Chemical Co., St. Louis, MO) 
(52). At the end of the incubation period, culture 
supernatants were harvested by centrifugation, sterilized by 
filtration through a 0.22 micron filter membrane, and 
assayed for biological activity. The crude supernatant 
contained 2 , 896 U/ml of IL-2. The cell-free supernatant was 
concentrated on an Amicon PM-10 membrane (Amicon 
Corporation, Lexington, MA), and dialyzed against serum-free 
medium. 
of IL-2. 
The concentrated supernatant contained 16,000 U/ml 
Measurement of IL-2 Production by 
Splenocytes 
Interleukin-2 production of chimeras and B6 mice was 
determined by culturing splenocytes (1.0 x 10 6 ) with 2 ug/ml 
of Con-A for 24 hr. After incubation, supernatants were 
collected, filtered through a 0.22 micron membrane, and 
assayed for IL-2 production using HT-2 cells. 
Determination of IL-2 Activity 
Measurement of IL-2 activity was performed using the 
standard microassay (26). HT-2 cells (American Type Culture 
Collection, Rockville, MD.), an IL-2 dependent murine helper 
T-cell line (21), were maintained in complete medium 
supplemented with IL-2. HT-2 cells were used as the target 
cell population in the IL-2 microassay. HT-2 cells were 
washed twice in complete medium and resuspended to a 
concentration of 5.0 x 10 4 cells/ml. A volume of 0.1 ml 
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(5.0 x 10 3 ) of HT-2 cells was placed in wells of 
microculture plates (Corning Glass Works, Corning, NY) to 
which serial 2-fold dilutions of test supernatants 
containing IL-2 had been prev~ously added. Wells containing 
HT-2 cells with a standard known quantity of IL-2, and wells 
containing medium alone served as IL-2 and medium controls, 
respectively. Plates were incubated at 37°c in a humidified 
atmosphere of 5% co2 in air for 24 hr. Following 
incubation, each microwell culture was pulsed for an 
additional 4 hr with 1 uCi of tritiated thymidine ( 3H-Tdr) 
(New England Nuclear, Boston, MA). Cultures were harvested 
onto glass-fiber filter strips (Skatron Inc., Sterling, VA). 
Filter strips were dried, placed in scintillation vials, and 
4 ml of scintillation fluid (Fisher Scientific Co., Fair 
Lawn, NJ) was added. Thymidine incorgoration was used as an · 
index of culture proliferation and measured with a liquid 
scintillation counter. 
The IL-2 activity was quantified by probit analysis of 
3tt~Tdr incorporation data (26). The transformation of data 
for probit analysis was accomplished by assigning a value of 
100% to the maximum counts per minute (cpm) of 3H-Tdr 
incorporated by HT-2 cells. All other data points were 
calculated as a percentage of the maximum. The percentages 
of maximum cpm were plotted against the reciprocal of sample 
dilution and IL-2 ac.tivity was · expressed in units. One unit 
is defined as the reciprocal of the dilution of test 
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supernatant that results in 50% of the maximum incorporation 
of 3 H-Tdr by HT-2 cells. 
Preparation of ·spleen and Thymus Cells 
Spleen and thymus glands were aseptically removed and 
gently teased into a suspension in complete medium. 
Cellular debris was allowed to settle by placing cells on 
ice for 5 minutes. Cells were washed once with complete 
medium. · The number of viable lymphocytes was determined by 
trypan blue exclusion using a hemacytometer. Cells were 
adjusted to the desired concentration in culture medium for 
in vitro assays. 
Response to In Vivo Immunization With SRBC 
The ability of chimeras to respond to in vivo 
sensitization with SRBC was evaluated. Control B6 and 
B6-AKR chimeras were injected intraperitoneally with 1 ml of 
1% SRBC (Colorado Serum Co., Denver, CO). Five days later, 
spleens were aseptically removed and gently homogenized. 
The viable cell concentration was adjusted to 1.0 x ·10 7 
cells/ml. One milliliter of each splenocyte suspension was 
centrifuged, the supernatant removed, and 0.2 ml of complete 
medium added to the cell pellet. Plaque forming cell (PFC) 
responses were analyzed using a modified form of the Jerne 
plaque assay described by Cunningham (53). A suspension of 
the antibody-producing cells (0.05 ml) was mixed with 
-
complement (0.05 ml) and target SRBC (0.05 ml) which had 
been washed 3 times in complete medium. A volume (0.05 ml) 
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of the mixture was pipetted onto the glass at the inner edge 
of the chamber which was then drawn into the chamber by 
capillary action. Chambers were sealed with stopcock 
grease. Slides were incubated at 37°c for 20 minutes. The 
number of plaques (clear zones of lysed SRBC surrounding a 
central lymphocyte) was determined using light microscopy. 
In Vivo Administration of IL-2 
Murine IL-2 (16,000 U/mouse) was administered daily by 
. intraperitoneal injection for 5 days. The initial dose of 
IL-2 (16,000 U) was mixed with a 1% washed SRBC (1 ml) 
suspension. On day 5 chimeras were sacrificed, and spleens 
were aseptically removed. Plaque forming cell responses of 
splenocytes to in vivo immunization with SRBC were measured 
(53). 
Mitogenic Assays 
In vitro proliferative responses to various mitogens 
were evaluated using B6 and B6-AKR chimeric lymphoid cells 
obtained from spleen and thymus. Lymphoid cells were 
cultured following the technique described by Alder et al. 
(54). Routinely, 2.0 x 105 lymphocytes were cultured in 
complete medium in triplicate wells of microtiter test 
plates. Purified PHA (Sigma Chemical Co., St. Louis, MO) at 
2.5, 5.0, 10.0, and 20.0, ug/ml and Con-A (Pharmacia, 
Piscataway, NJ) at 1, 2, 4, and 8 ug/ml were added to 
cultures. All cultures were incubated at 37°C in a 
humidified atmosphere of 5% co2 in air for 96 hr. During 
the last 24 hr, 1 uCi of 3H-Tdr was added to cultures. 
Cells were harvested onto glass-fiber filters. Filter 
strips were air dried and . placed in scintillation vials to 
which 4 ml of scintillation fluid was added. Cell 
proliferation was determined by the amount of 3H-Tdr 
incorporated into DNA by liquid scintillation counting. 
Results were expressed as cpm/culture (cpm with mitogen -
cpm with medium), with each value being the mean of three 
determinations. 
In Vitro Effect of RhIL-2 on 
Splenocyte Mitogenic Responses 
The effect of rhIL-2 on proliferative responses of 
splenocytes to PHA and Con-A was analyzed. Recombinant 
-
human IL-2 was added at various concentrations 25, 50, and 
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100 U/well to splenocyte cultures that were stimulated with 
various concentrations of Con-A (1, 2, 4, and 8 ug/ml) or 
PHA (2.5, 5.0, 10.0, and 20.0 ug/ml) -for a 48 hr culture 
period. All cultures were established in triplicate for a 
total of 96 hr at 37°c, with 5% co2 in air. During the last 
24 hr, 1 uCi of 3H-Tdr was added to cultures. At the end of 
the incubation period, cells were collected onto glass-fiber 
filters. Lymphocyte proliferative responses to PHA and 
Con-A in the absence and presence of rhIL-2 were determined 
by liquid scintillation counting. 
Kinetics of the In Vitro Effect of RhIL-2 
on Mitogenic Responses 
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Kinetics of the rhIL-2 effect on splenocyte 
proliferative responses to mitogens were estab lished. In 
the first series of experiments, rhIL-2 {SOU/well) was 
added to mitogen stimulated cultures at various time points 
following culture initiation. Triplicate cultures were 
incubated for a total of 96 hr at 31°c, and 5% co2 in air. 
A volume of 0.05 ml of 3H-Tdr (1 uCi) was added to each well 
for the last 24 hr of the incubation period. Cells were 
collected on glass-fiber filters and cpm were determined by 
liquid scintillation counting. In some experiments, rhIL-2 
{SOU/well) was added to cultures at various time points (O, 
24, and 48 hr) after culture initiation. The duration of 
exposure to rhIL-2 was 72 hr for all cultures. Total PHA 
incubation times were 72, 96, and 120 hr. 
Assay for Activity of 
7D4 Monoclonal Antibody 
The hybridoma cell line (7 D4, CRL 1698, American Type 
Culture Collection) which produces 7D4 antibody to the 
murine IL-2 receptor was cultured in complete medium. 
Supernatant fluids containing the antibody were collected 
and filter sterilized through a 0.22 micron membrane filter. 
The IL-2 dependent HT-2 cell line was used to analyze 7D4 
activity. HT-2 cells (5.0 x 103 ) were incubated in the 
presence of various 2-fold dilutions of rhIL-2 (1/2, 1/4, 
1/8, 1/16, 1/32, 1/64 and 1/28), and 0.05 ml of 7D4 
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antibody. After 24 hr, 1 uCi of 3H-Tdr was added to each 
culture. Four hr later, proliferation was measured by the 
incorporation of 3H-Tdr into DNA. The percent inhibition of 
proliferation was calculated from the following formula: 
% inhibition= 1 _ cpm with antibody 
cpm without antibody 
X 100 
Effect of 7D4 Antibody on 
Proliferation of P815 Cells 
P815 cells (55), were cultured with 0.05 ml of 7D4 
antibody or complete medium for 24 hr. At the end of the 
incubation time, 1 uCi of 3H-Tdr was added to each culture. 
Four hr later, proliferation was measured by the 
incorporation of 3H-Tdr into DNA. 
Effect of 7D4 Antibody on 
Thymocyte Proliferation 
Thymocytes from B6 mice (2.0 x 105 cells/well). were 
cultured in 96-well flat-bottomed microculture plates with 
various concentrations of PHA (2.5, 5.0, 10.0, and 20.0 
ug/ml), rhIL-2 (50 U), and 0.05 ml of supernatants 
containing 7D4 antibody. Cultures were incubated for 3 or 4 
days. One uCi of 3H-Tdr was added to cultures for the last 
24 hr of incubation. Proliferation was measured by the 
incorporation of 3H-Tdr into: DNA. The percent inhibition of 
proliferation was measured as previously described. 
Effect of 7D4 Antibody on Mitogen-Induced 
Proliferation of Splenocytes 
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Splenocytes (2.0 x 10 5 cells/well) were cultured in 
96-well flat-bottomed microculture plates with various 
concentrations of Con-A (i, 2, and 4 ug/ml) or PHA (2.5, 
5.0, and 10.0 ug/ml) in the absence and presence of 0.05 ml 
of supernatants containing 7D4 antibody for 3 or 4 days. 
Cultures were pulsed for the last 24 hr with 3H-Tdr. After 
incubation, cultures were harvested and the percent 
inhibition of proliferation was determined. 
Statistics 
The statistical analysis used for the expression of the 
data were as follows. Mean+ standard error of the mean 
(SEM), and the student's t distribution (P values). 
RESULTS 
The Effect of In Vivo Administration of 
Murine IL-2 on the In Vivo SRBC Response and 
IL-2 Production of B6-AKR Chimeric s lenoc tes 
0 Days Post-transplant 
Chimeras were injected intraperitoneally with murine 
IL-2 for 5 days. On day 5, IL-2 production and PFC antibody 
response to SRBC were measured. Chimeras treated with IL-2 
demonstrated splenocyte PFC antibody response to SRBC 
compared to non-IL-2 treated chimeras. This response was 
lower compared to that of normal B6 mice (Table I). 
Interleukin-2 production in non-IL-2 treated chimeras was 
not significantly different (P>0.1) from that of normal B6 
mice (Table I). Interleukin-2 treatment of chimeras 
significantly suppressed IL-2 production (79%, P>0.01) 
compared to non-IL-2 treated chimeras (Table I). 
Effect of In Vivo Administration of RhIL-2 
on IL-2 Production and Proliferative 
Responses of Chimeric Splenocytes to Mitogeris 
Chimeras were injected daily for 5 days with rhIL-2 
(50,000 U). Splenocytes from rhIL-2 treated chimeras and 
control mice were cultured with various concentrations of 
PHA or Con-A for 96 hr. When the concentration of Con-A was 
either 4 or 8 ug/ml, rhIL-2 treatment of chimeras enhanced 
splenocyte proliferation. However, at lower concentrations 
(1 or 2 ug/ml of Con-A) no effect was observed (Table II). 
Interleukin-2 production was not significantly different 
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TABLE I 
Effects Of In Vivo Administration Of Murine IL-2 
On The In vivo SRBC Responses And IL-2 Production 
Of Normal And Chimeric Splenocytes 
MICE 








Xl0 IL-2a PLAQUES (U/ml) 
B6(2)b 











aIL-2 administered in vivo (80 000 U/mouse) 
bNumber of animals 






Effects Of In Vivo Administration Of RhIL-2 On Con-A Mitogenesis 
And IL-2 Production Of Chimeric Splenocytes 
(120 Days Post-transplant) 
3H-Tdr uptake (cpm)b 
CON-A 
MICE IL-2a lug/ml 2 ug/ml 4 ug/ml 
B6(3)c 74,821,:!:2,136 64,046,:!:16,979 36,567,:!:ll,753 
B6-AKR(2) 49,808,:!:10,194 45,999,:!:3,557 20,823,:!:828 
B6-AKR(4) + 53,560,:!:4,228 43,723,:!:l,093 22,849,:!:411 
aIL-2 administered in vivo (250 000 U/mouse) 
bMean proliferative responses of animals tested+ SEM 
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(P>0.1) for rhIL-2 treated chimeras compared to non-IL-2 
treated chimeras and normal B6 mice (Table II). Recombinant 
human IL-2 treatment of chimeras had no significant effect 
(P>O.l) on PHA responsiveness of their splenocytes compared 
to non-IL-2 treated chimeras (Table III). 
In Vitro Effect of RhIL-2 on Con-A Mitogenesis 
of Normal and Chimeric Splenocytes 
(50 Days Post-transplant) 
Splenocytes of chimeras and age-matched normal B6 mice 
were cultured with various concentrations of Con-A for 96 
hr. Recombinant human IL-2 was added to splenocyte cultures 
48 hr after culture initiation. In the absence of rhIL-2, 
splenocytes from B6 mice proliferated in response to 1, 2, 
and 4 ug/ml of Con-A. The proliferative response was 
maximum at 1 ug/ml. Recombinant human IL-2 at various 
concentrations had no effect on Con-A mitogenesis of B6 
splenocytes compared to cultures without rhIL-2 (Figure 1). 
Splenocytes from chimeras proliferated in response to 1 and 
2 ug/ml of Con-A. Maximum proliferation occurred at 1 
ug/ml. Recombinant human IL-2 at various concentrations had 
no effect on Con-A mitogenesis of chimeric splenocytes 
compared to cultures without rhIL-2 (Figure 2). 
In Vitro Effect of RhIL-2 on PHA Mitogenesis 
of Normal and Chimeric Splenocytes 
(50 Days Post-transplant) 
Splenocytes of chimeras and age-matched normal B6 mice 
were cultured with various concentrations of PHA for 96 hr. 
TABLE III 
In Vivo Effect Of RhIL-2 On PHA 
Responsiveness Of Chimeric Splenocytes 
(120 Days Post-transplant) 
3H-Tdr Uptake (cpm)b 
PHA 
Mice IL-2a 5ug/ml lOug/ml 20ug/ml 
B6(3)c 7,329+529 4,061+305 3,157~530 
B6-AKR(2) - 2,075+518 2,188~754 1,562~405 






aIL-2 administered in vivo (250 000 U/mouse) 
b Mean proliferative responses of animals tested+ SEM 
cNumber of animals 
Figure 1. In Vitro Effects of RhIL-2 on Con-A Mitogenesis 
of B6 Splenocytes (50 Days Post-transplant). 
Each point represents average values of 3 mice! 
SEM. 
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Figure 2. In Vitro Effects of RhIL-2 on Con-A Mitogenesis 
of Chimeric Splenocytes (50 Days Post-
transplant). 
Each point represents average values of 3 mice+ 
SEM. 
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Recombinant human IL-2 was added to cultures 48 hr after 
culture initiation. 
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Splenocytes from normal B6 mice proliferated in 
response to various concentrations of PHA. This 
proliferative response demonstrated a Gaussian distribution 
which was skewed to the right (Figure 3). Maximum 
proliferation occurred at 10 ug/ml qf PHA. Recombinant 
human IL-2 at various concentrations increased proliferative 
responses to PHA at 2.5 and 5.0 ug/ml compared to cultures 
without rhIL-2. Increases in proliferative responses were 
7.5 fold (P<0.05) and 4.0 fold (P<0.01), respectively 
(Figure 3). Splenocytes from chimeras demonstrated low 
proliferative responses to PHA at various concentrations 
tested (Figure 4). Addition of rhIL-2 at various 
concentrations significantly enhanced proliferative 
responses to PHA compared to cultures without rhIL-2. 
Increases in proliferative responses to PHA were 10.0 fold 
(P<0.01), 6.0 fold (P<0.01), 4.8 fold (P<0.05), and 2.5 fold 
(P<0.025) at 2.5, s.o, 10.0, and 20.0 ug / ml, respectively. 
Maximum proliferation occurred at 10 ug/ml of PHA in the 
presence of various concentrations of rhIL-2 (Figure 4). 
In Vitro Effect of RhIL-2 on Con-A Mitogenesis 
(70 Days Post-transplant) 
of Normal and Chimeric Splenocytes 
Recombinant human IL-2 was added to Con-A stimulated 
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Figure 4. In Vitro Effects of RhIL-2 on PHA Mitogenesis 
of Chimeric Splenocytes (50 Days Post-
transplant). 
Each point represents average values of 3 mice+ 
SEM. 
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Figure 5. In Vitro Effects of RhIL-2 on Con-A Mitogenesis 
of B6 Splenocytes (70 Days Post-transplant). 
Each point represents average values of 3 mice! 
SEM. 
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Addition of rhIL-2 at various concentrations had no 
effect on Con-A mitogenesis of either normal (Figure 5), 
chimeric splenocytes (Figure 6), compared to cultures 
without rhIL-2. 
In Vitro Effect of RhIL-2 on PHA Mitogenesis 
of Normal and Chimeric Splenocytes 
(70 Days Post-transplant) 
Splenocytes from normal B6 mice proliferated in 
response to various concentrations of PHA. Maximum 
_proliferation occurred at 10 ug/ml of PHA. Addition of 
various concentrations of rhIL-2 increased proliferative 
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responses to PHA at 2.5 and 5.0 ug/ml compared to splenocyte 
cultures without rhIL-2. Increases in proliferative 
responses were 3.1 fold (P<0.01) and 1.5 fold (P>0.01), 
respectively (Figure 7). 
Splenocytes from chimeras showed maximum proliferative 
responses to PHA at 5 and 10 ug/ml (Figure 8). Addition of 
various concentrations of rhIL-2 significantly increased 
proliferative responses to PHA at 2.5 and 5.0 ug/ml compared 
to cultures without rhIL-2. Increases were 2.0 fold 
(P>0.05) and 1.7 fold (P>0.01), respectively. In the 
presence of rhIL-2 maximum proliferation occurred at 5 ug/rnl 
of PHA (Figure 8). 
In Vitro Effect of RhIL-2 on Con-A Mitogenesis 
(130 Days Post-transplant) 
of Normal and Chimeric Splenocytes 
In the following experiment, SOU of rhIL-2 was added 
to Con-A stimulated splenocytes 48 hr after culture 
Figure 6. In Vitro Effects of RhIL-2 on Con-A Mitogenesis 
of Chimeric Splenocytes ( 70 Days Post-
transplant). 
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Figure 7. In Vitro Effects of RhIL-2 on PHA Mitogenesis of 
B6 Splenocytes (70 Days Post-transplant). 
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Figure 8. In Vitro Effects of RhIL-2 on PHA Mitogenesis of 
Chimeric Splenocytes (70 Days Post-transplant). 
Each point represents average values of 3 mice+ 
SEM. 
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initiation. In the absence of rhIL-2, splenocytes from B6 
mice showed proliferative responses to Con-A at 1, 2, and 4 
ug/ml (Figure 9). Proliferative responses of B6 splenocytes 
to Con-A (1 and 2 ug/ml) were enhanced after rhIL-2 addition 
compared to cultures without rhIL-2. However, the 1.5 fold 
increase in proliferation was significant (P<0.025) only at 
1 ug/m of Con-A {Figure 9). 
The 1.3 fold increase in proliferative response of 
chimeric splenocytes to Con-A (1 ug/ml) was significant 
{P<0.05) after the addition of rhIL-2 compared to cultures 
without rhIL-2 (Figure 10). 
In Vitro Effect of RhIL-2 on PHA Mitogenesis 
of Normal and Chimeric Splenocytes 
(130 Days Post-transplant) 
In the absence of rhIL-2, B6 splenocytes showed maximum 
proliferative response to 10 ug/ml of PHA. In the presence 
of rhIL-2, significant enhancement of proliferation occurred 
at 2.5 and 5.0 ug/ml compared to cultures without rhIL-2. 
Increases in proliferative responses were 6.3 fold (P>0.05) 
and 5.8 fold (P>0.01), respectively (Figure 11). In the · 
presence of rhIL-2, maximum proliferation was shifted from 
10 to 5 ug/ml (Figure 11). 
In the absence of rhIL-2, chimeric splenocytes showed 
m~ximum proliferation to 10 ug/ml of PHA. In the presence 
of rhIL-2, proliferation was enhanced to 2.5, 5.0, and 10.0 
ug/ml of PHA compared to cultures witbout rhIL-2. Increases 
in proliferative responses were 2.5 fold (P<0.05), 6.0 fold 
(P>0.01), and 1.9 fold (P>0.01), respectively. In the 
presence of rhIL-2, maximum proliferation was shifted from 
10 to 5 ug/ml (Figure 12). 
Kinetics of the Enhancing Effect of RhIL-2 
on Mitogenic Responses of B6 Splenocytes 
Splenocytes from normal B6 mice were cultured with 
Con-A or PHA for 96 hr. Recombinant human IL-2 (50 U) was 
added to splenocyte cultures at various time points after 
culture initiation. Recombinant human IL-2 significantly 
increased splenocyte responsiveness (1.5 to 3.0 fold, 
P<0.05) to Con-A at 1 and 2 ug/ml compared to cultures 
without rhIL-2 (Figure 13). These increases were similar 
for each culture regardless of the time of rhIL-2 addition. 
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Recombinant human rhIL-2 significantly increased 
splenocyte responsiveness (5.2 to 100 fold, P>0.005) to PHA 
at 2.5, 5.0, and 10.0 ug/ml compared to cultures without 
rhIL-2. However, the degree of enhancement decreased when 
rhIL-2 was added at 24 and 48 hr compared to 0, 0.5, and 1 
hr cultures (Figure 14). 
Effect of RhIL-2 Exposure Time 
on PHA Mitogenesis of B6 Splenocytes 
Recombinant human IL-2 (50 U) was added to PHA 
stimulated cultures at 0, 24, and 48 hr after culture 
in~tiation. Incubation time with rhIL-2 was constant (72 
hr) for all cultures. Therefore, total incubation time for 
PHA cultures were 72, 96, and 120 hr. 
Figure 9. In Vitro Effects of RhIL-2 on Con-A Mitogenesis 
of B6 Splenocytes (l30 Days Post-transplant). 
Each point represents average values of 3 mice+ 
SEM. 
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Figure 10. In Vitro Effects o f RhIL-2 on Con-A Mitogenesi s 
of Chimeric Splenocytes (130 Days Post-
transplant). 
Each point represen t s average value s of 3 mice 
+ SEM. 
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Figure 11. In Vitro Effects of RhIL-2 on PHA Mitogenesis 
of B6 Splenocytes (130 Days Post-transplant). 
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Figure 12. In Vitro Effects of RhIL - 2 on PHA Mitoge nes i s 
of Chimeric Splenocytes (130 Days Post -
transplant). 
Each point represent s average value s of 3 mi ce 
+ SEM. 
60 
g 50 -0- NO IL-2 = .. ... 50UIL-2 .-4 40 
~ 
~ 30 :,. 
20 ... 
0 
f 10 u 
0------------------------.. 
0 2.5 5 10 20 3 0 
CONCENTRATION OF PHA {ug/ml) 
Figure 13. Kinetics of the Enhancing Effects of RhIL-2 on 
Con-A Mitogenesis of B6 Splenocytes. 
Each bar represents average values of 3 mice 
+ SEM. 
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Figure 14. Kinetics of the Enhancing Effects of RhIL-2 on 
PHA Mitogenesis of B6 Splenocytes. 
Each bar represents average values of 3 mice 
+ SEM. 
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Proliferative response of splenocytes to PHA (5 ug/ml) 
was enhanced when rhIL-2 was added at O, 24, and 48 hr 
compared to cultures without rhIL-2. The degree of 
enhancement was similar for all cultures, regardless of the 
total PHA incubation time (Figure 15). 
Kinetics of RhIL-2 Enhancing Effect 
on Mitogenic Responses of B6 Thymocytes 
48 
Thymocytes from normal mice were cultured with Con-A or 
PHA for 96 hr. Recombinant human IL-2 (50 U) was added to 
splenocyte cultures at various time points after culture 
initiation. Recombinant human IL-2 (50 U) significantly 
increased thymocytes responsiveness (P<0.05) to Con-A at 1 
and 2 ug/ml compared to cultures without rhIL-2. However, 
the degree of- enhancement varied for each culture in 
relation to the time of rhIL-2 addition and the 
concentration of Con-A used. No enhancement was observed in 
cultures in which rhIL-2 was added at 48 hr (Figure 16). 
Addition of rhIL-2 (50 U) to thymocytes at O, 0.5, and 
1 hr after culture initiation increased proliferative 
responses to PHA compared to . cultures without rhIL-2. The 
degree of enhancement was greater for cultures stimulated 
with 10.0 ug/ml of PHA compared to those stimulated with 2.5 
and 5.0 ug/ml. The level of enhancement decreased in all 
PHA cultures when rhIL-2 was added at 24 and 48 hr after 
culture initiation (Figure 17). 
Figure 15. The Effect of IL-2 Exposure Time on PHA 
Mitogenesis of B6 Splenocytes. 
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Figure 16. Kinetics of the Enhancing Effects of RhIL-2 on 
Con-A Mitogenesis of B6 Thymocytes. 
Each bar represents average values of 3 mice 
+ SEM. 
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Figure 17. Kinetics of the Enhancing Effects of RhIL-2 o n 
PHA Mitogenesis of B6 Thymocytes. 
Each bar represents average values of 3 mice 
+ SEM. 
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Effect of 7D4 Antibody on Proliferation 
of HT-2 Cells 
52 
HT-2 cells were cultured with various concentrations of 
rhIL-2 in the absence or presence of 7D4 antibody (25% by 
volume) for 24 hr. The 7D4 antibody greatly inhibited the 
proliferation of HT-2 cells (>80%) at all dilutions of 
rhIL-2 tested (Figure 18). 
Effect of 7D4 Antibody on 
Proliferation of P815 Cells 
P815 cells were incubated with various concentrations 
of 704 antibody for 24 hr. The 7D4 antibody did not inhibit 
proliferation of P815 cells at any of the concentrations 
tested (Table IV). 
Analysis of the Effectiveness of 7D4 
Antibody on Proliferation of Thymocytes to 
PHA and RhIL-2 
Thyrnocytes from B6 mice were cultured with various 
concentrations of PHA and rhIL-2 (50 U) in the absence or 
presence of 7D4 antibody (25% by volume) for 3 or 4 days • 
. 
The 7D4 antibody inhibited thymocyte proliferation to PHA 
and rhIL-2 at all concentrations of PHA on both days 3 and 
4. This inhibition ranged from 77 to 98% (Table V). 
Effect of 7D4 Antibody on 
Con-A and PHA Mitogenesis of Splenocytes 
Splenocytes from B6 mice were cultured with various 
concentrations of PHA or Con-A in the absence or presence of 
704 antibody. The 7D4 antibody consistantly inhibited the 
prol.iferation of spl.enocytes to Con- A or PHHA. J[mJtniUt» "tt::iicom <mff 
PHA mitogenesis ranged from 82 to 901 on day 3 aBIIOOli $$~ tt:aD 
89% on day 4. Inhibition of Con- A mritogemies.is :irann~ :fEltCm:m 
76 to 98% on day 4 (Tabl.e VI). 
Figure 18. Effect of 704 Antibody on IL-2 Dependent 
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Effect Of 7D4 Antibody On The Proliferation 
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IL-2 plays a major role in the regulation of immune 
responses (26-28). 
Utilizing both in vivo and in vitro assays, the 
effectiveness of IL-2 in the enhancement of immune responses 
in B6-AKR and normal B6 mice was investigated. 
Chimeras [B6-AKR] are unable to generate anti-SRBC PFC 
responses (2,3). In this study, chimeras were analyzed for 
their ability to generate PFC responses to SRBC after in 
vivo treatment with murine IL-2. In vivo treatment of 
chimeras with murine IL-2 partially restored PFC responses 
of their splenocytes to SRBC. There are two possible 
explanations for this limited restoration of PFC responses 
in these chimeras. The first possibility is that IL-2 
directly affected B-cell differentiation to an antibody 
producing state. Therefore, the requirement for T-cell help 
was bypassed for SRBC responsiveness. It has been shown 
that IL-2 can directly bind to B-cells and stimulate 
antibody responsiveness (56). The second possibility is 
that IL-2 treatment expanded a minor subpopulation of helper 
T-cells described previously in these chimeras (11,12). 
These cells can interact with donor type cells in H2-I 
incompatible chimeras. Ultimately, these helper T-cells act 
as essential elements in the PFC response to SRBC (11,12). 
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The fact that these chimeras respond to a secondary 
stimulation with SRBC (2,3), support the idea that these 
minor subpopulations do exist, and are expanded by antigen 
(SRBC)-induced IL-2. 
Treatment of chimeras with murine IL-2 suppressed 
splenocyte production of IL-2. This suppressed IL-2 
production was probably due to the presence of T-cell 
specific suppressor factors in the crude preparations of 
murine IL-2 used. The presence of such suppressor factors 
has been previously reported in supernatants of 
alloantigen-activated splenocytes (57). 
In order to determine the intrinsic role of IL-2 in 
restoration of PFC responses in chimeras, it was essential 
to use homogenously pure IL-2. Treatment of chimeras with 
the highly purified IL-2 (rhIL-2) failed to restore PFC 
responses in these chimeras (data not shown). However, 
treatment of chimeras with rhIL-2 did not suppress IL-2 
production of their splenocytes. This finding further 
supports the hypothesis that the suppression of IL-2 
production in murine IL-2 treated chimeras is due to the 
presence of suppressor factors in the crude preparations 
used. In vivo treatment of chimeras with rhIL-2 resulted in 
a slight enhancement of mitogenic responses at higher, but 
not lower concentrations of Con-A. However, rhIL-2 
treatment had no significant effect on mitogenic responses 
of their splenocytes to various concentrations of PHA. The 
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fai1ure of rhIL-2 treatment to significant1y enhance 
mitogenic responses to Con-A or PHA could be directly 
related to the dose of -IL-2 used, and/or its short serum 
half life (58). Therefore, the saturating levels of IL-2 
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could never be attained in these chimeras with the treatment 
regimens used. 
Since the use of rhIL-2 in vivo failed to significantly 
enhance these immune functions, the effect of rhIL-2 on 
sp l enocyte mitogenesis was studied in vitro. The effect of 
rhIL-2 in vitro was evaluated using three groups of normal 
B6 and chimeric mice. Several observations were made when 
responses of these mice were compared. Younger chimeras (50 
days post-transplant) were suppressed in their responses to 
PHA compared to the other age groups. The low PHA response 
in these chimeras was enhanced by rhIL-2 addition • . In 
genera1, presence of rhIL-2 in PHA cultures enhanced 
mitogenesis of splenocytes from B6 and chimeric mice 
regardless of their age. When Con-A was used as the 
mitogen, rhIL-2 enhanced proliferation of older (130 days 
post-transplant), but not younger chimeras (50 and 70 days 
post-transplant). Fully a1logeneic B6-AKR chimeras are 
unable to produce normal levels of IL-2 at later stages 
post-transplant (> 100 days) (3). 
In the present study, 
enhancement of mitogenic responses by rhIL-2 to PHA a nd 
· 1:·-nd1·cate that despite their Con-A in older chimeras, 
. th re capable of responding 
deficiency in IL-2 production ey a 
61 
to IL-2 in mitogenic assays in vitro. This enhanced 
mitogenic response could be due to the ability of IL-2 to 
u p regulate its own receptor expression (59,60). These 
findi ngs are similar to the results of studies using 
perip heral blood from BMT patients ( 61 , 62). In these 
experi me nts, patients who were transplanted with bone marrow 
were unab le to produce IL-2, but could respond to IL-2 when 
added to lymphocyte cultures. 
In this study, the inability of younger chimeras to 
show enhanced Con-A mitogenesis to exogenous rhIL-2 in 
v i tro, suggests that different mechanisms are involved in 
the activation of splenocytes with PHA versus Con-A. This 
suggestion is directly related to differences in the level 
of endogenous IL-2 in these two mitogenic assays. 
Splenocytes stimulated with Con-A proguce high levels of 
IL-2 (26). However, PHA stimulated splenocytes produce very 
low levels of IL-2 (46). Therefore, one coul~ speculate 
that in younger chimeras which have normal levels of 
en~ogenous IL-2, its receptors on Con-A activated 
splenocytes were fully occupied with endogenous IL-2. Thus, 
the number of receptors available for exogenous IL-2 were 
limiting for the enhancement of splenocyte proliferation to 
Con-A. These findings may indicate that PHA mitogenic 
assays are more appropriate in the evaluation of enhancing 
effects of exogenous IL-2 due to the absence of interfering 
concentrations of endogenous IL-2. 
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In order to determine the critical parameter for the 
enhancement of mitogenic responses with rhIL-2, studies on 
the kinetics of its enhancing effect were performed. Since 
the immunological state of fully allogeneic B6-AKR chimeras 
has not been well characterized, studies were performed with 
lymphoid cells from normal B6 mice (hemopoietic system of 
B6-AKR chimeras). When rhIL-2 was added to 96 hr splenocyte 
cultures at various time points, Con-A responses were 
greatly enhanced in all cultures, regardless of the total 
exposure time to rhIL-2. However, maximum enhancement of 
PHA mitogenesis occurred when rhIL-2 was added at O and 1 hr 
after culture initiation. This degree of enhancement tended 
to decrease when rhIL-2 was added at 24 or 48 hr. In these 
experiments, there were two variables: the time of rhIL-2 
addition, and the . total incubation period with rhIL-2. In 
order to determine which of these variables influenced the 
level of enhancement, the incubation time with rhIL-2 was 
kept constant for all cultures. Similar levels of 
enhancement were demonstrated for all cultures, regardless 
of the time of rhIL-2 addition. The length of incubation 
time with exogenous IL-2 was the limiting factor in the 
enhancement of PHA mitogenesis. These findings, further 
supported the speculation that different mechanisms are 
involved in PHA stimulation of splenocytes compared to 
Con-A. Splenocytes stimulated with PHA bear lower numbers 
of IL-2 receptors, and produce a limited amount of 
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endogenous IL-2 compared to Con-A stimulated cultures (46). 
These limitations in PHA stimulated cultures could result in 
the requirement for longer incubation time with exogenous 
rhIL-2. Alternatively, enhanceraent of proliferation to PHA 
could be due to IL-2 receptor upregulation by exogenous 
rhIL-2. Maximum enhancement would then require upregulation 
of the number of receptors to optimal levels. Upregulation 
of a low number of IL-2 receptors would require a longer 
.exposure time to rhIL-2. 
In order to provide further evidence to support 
speculations made for the kinetics of PHA stimulated 
splenocytes, similar kinetic studies were performed on 
thymocytes. Thymocytes cultured with Con-A release 1% to 2% 
of the level of IL-2 produced by Con-A stimulated 
splenocytes (20). A small percentage of activated 
thymocytes express IL-2 receptors (46). According to these 
findings (20,46), thymocytes should demonstrate similar 
kinetics to that shown by PHA stimulated splenocytes. The 
results indicated that thymocytes required a similar 72 to 
96 hr exposure time to exogenous rhIL-2 for maximum 
enhancement to occur. Thus, PHA stimulated splenocytes and 
thymocytes follow the same kinetic due to the limitation of 
endogenous IL-2 and IL-2 receptors. 
The 7D4 monoclonal antibody was used as a specific 
inhibitor of IL-2 function in mitogenic assays. The 
proliferation ~f -splenocytes to different concentrations of 
64 
PHA or Con-A was markedly inhibited by 7D4 antibody. Malek 
et al. (46) had previously reported that the mixture of 7D4 
and 3C7 failed to significantly inhibit the proliferation of 
splenocytes to optimal concentrations of Con-A or PHA. The 
inhibition of splenocyte proliferation to Con-A or PHA by 
7D4, in the present study, could be due to a non-specific 
action of the 7D4 antibody. However, the result of 
experiments in which 7D4 antibody was tested on an unrelated 
cell line, P815, ruled out this possibility. Proliferation 
of thymocytes to PHA and rhIL-2 was greatly inhibited by 7D4 
antibody. This finding was consistant with those previously 
reported by Malek et al. (46). Therefore, studies with 7D4 
antibody provide direct evidence for the involvement of IL-2 
in the proliferation of splenocytes to T-cell mitogens and 
the proliferation of thyrnocytes in co-stimulatory assays. 
In summary, critical parameters for examining the 
mitogenic response of chimeras to T-cell mitogens and 
exogenous IL-2 were identified. Future studies will 
evaluate IL-2 receptor expression on mitogen induced T-cell 
blasts from chimeras and B6 mice. These experiments will 
determine if similar types of parameters are associated with 
immunodeficiencies of long-term surviving, fully allogeneic 
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